Defining the Time-Limited Trial for Patients with Critical Illness: An Official American Thoracic Society Workshop Report
Authors:
- Jacqueline M. KruserJKJacqueline M. Kruser
- Deepshikha C. AshanaDADeepshikha C. Ashana
- Katherine R. CourtrightKCKatherine R. Courtright
- Erin K. KrossEKErin K. Kross
- Thanh H. NevilleTNThanh H. Neville
- Eileen RubinEREileen Rubin
- Yael SchenkerYSYael Schenker
- Donald R. SullivanDSDonald R. Sullivan
- J. Daryl ThorntonJTJ. Daryl Thornton
- Elizabeth M. VigliantiEVElizabeth M. Viglianti
- Deena Kelly CostaDCDeena Kelly Costa
- Claire J. CreutzfeldtCCClaire J. Creutzfeldt
Top Cited Papers
Open Access
- 1 February 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (2) , 187-199
Abstract
In critical care, the specific, structured approach to patient care known as a “time-limited trial” has been promoted in the literature to help patients, surrogate decision makers, and clinicians navigate consequential decisions about life-sustaining therapy in the face of uncertainty. Despite promotion of the time-limited trial approach, a lack of consensus about its definition and essential elements prevents optimal clinical use and rigorous evaluation of its impact. The objectives of this American Thoracic Society Workshop Committee were to establish a consensus definition of a time-limited trial in critical care, identify the essential elements for conducting a time-limited trial, and prioritize directions for future work. We achieved these objectives through a structured search of the literature, a modified Delphi process with 100 interdisciplinary and interprofessional stakeholders, and iterative committee discussions. We conclude that a time-limited trial for patients with critical illness is a collaborative plan among clinicians and a patient and/or their surrogate decision makers to use life-sustaining therapy for a defined duration, after which the patient’s response to therapy informs the decision to continue care directed toward recovery, transition to care focused exclusively on comfort, or extend the trial’s duration. The plan’s 16 essential elements follow four sequential phases: consider, plan, support, and reassess. We acknowledge considerable gaps in evidence about the impact of time-limited trials and highlight a concern that if inadequately implemented, time-limited trials may perpetuate unintended harm. Future work is needed to better implement this defined, specific approach to care in practice through a person-centered equity lens and to evaluate its impact on patients, surrogates, and clinicians.Keywords
This publication has 58 references indexed in Scilit:
- Discussion of treatment trials in intensive careJournal of Critical Care, 2013
- Treatment Decisions After Severe StrokeStroke, 2012
- The Influence of Race/Ethnicity and Socioeconomic Status on End-of-Life Care in the ICUChest, 2011
- Reducing racial disparities in pain treatment: The role of empathy and perspective-takingPain, 2011
- Racism in healthcare: Its relationship to shared decision-making and health disparities: A response to BradbySocial Science & Medicine, 2010
- Opiniones: End‐of‐Life Care Preferences and Planning of Older LatinosJournal of the American Geriatrics Society, 2010
- Racial Differences in Self-Reported Exposure to Information about Hospice CareJournal of Palliative Medicine, 2009
- Unraveling the relationship between literacy, language proficiency, and patient–physician communicationPatient Education and Counseling, 2009
- Voices of African American, Caucasian, and Hispanic Surrogates on the Burdens of End-of-Life Decision MakingJournal of General Internal Medicine, 2008
- Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study Commentary: Why do doctors overestimate? Commentary: Prognoses should be based on proved indices not intuitionBMJ, 2000